Geistlich Pharma North America, Inc. Announces Acquisition of Lynch Biologics, LLC
OCTOBER 26, 2022 — Geistlich Pharma North America is proud to announce the acquisition of Lynch Biologics, LLC, the developer, and sole provider of GEM 21S®, the first recombinant growth factor product for use in oral regenerative surgery. This acquisition further strengthens the regenerative product portfolio of Geistlich and provides significant growth potential.
The combination of two regenerative leaders offers:
- Expanded regenerative solutions for clinicians and their patients
- A combined team of purpose-driven leaders and highly skilled experts
- Strengthened product development, clinical research, and education on new regenerative technologies
- A shared commitment to research, quality, and safety
Listen below as Les Burrows, General Manager of Geistlich Pharma North America, and Sam Lynch, DMD, DMSC, CEO of Lynch Biologics, discuss the details of the acquisition, the benefits to our customers, and the opportunities this brings to support our mission to drive regeneration.
To learn more, please contact our Customer Care toll-free at 855-799-5500 or email us directly at email@example.com.